Gainers
- Avadel Pharmaceuticals plc (NASDAQ:AVDL) shares rose 60.2% to $1.7136. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for experimental narcolepsy drug.
- Oncternal Therapeutics, Inc. (NASDAQ:ONCT) rose 36.9% to $1.12. Oncternal Therapeutics presented updated interim data for zilovertamab in combination with ibrutinib at ASCO 2022.
- Allarity Therapeutics, Inc. (NASDAQ:ALLR) gained 25.3% to $2.58 after Ladenburg Thalmann initiated coverage on the stock with a Buy rating and an $8 price target.
- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) shares rose 25% to $16.50. PMV Pharmaceuticals announced initial PC14586 Phase 1 clinical data to be presented at the 2022 American Society of Clinical Oncology Annual Meeting June 7.
- Merus N.V. (NASDAQ:MRUS) gained 23.3% to $17.24. Merus announced the publication of abstract of Zenocutuzumab in NRG1-fusion (NRG1+) cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
- Red Robin Gourmet Burgers, Inc. (NASDAQ:RRGB) rose 21.8% to $10.49 after the company reported better-than-expected Q1 results.
- Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) surged 20.2% to $19.98.
- Farfetch Limited (NASDAQ:FTCH) gained 18.8% to $9.13 following Q1 results.
- Houston American Energy Corp. (NASDAQ:HUSA) jumped 18.6% to $3.8450.
- SoundHound AI, Inc. (NASDAQ:SOUN) jumped 18.5% to $7.73.
- SIGA Technologies, Inc. (NASDAQ:SIGA) jumped 18.3% to $11.40. European Union has agreed to buy Bavarian Nordic's Imvanex, Tecoviriat from Siga in the US.
- Omega Therapeutics, Inc. (NASDAQ:OMGA) gained 18% to $2.62.
- Solo Brands, Inc. (NYSE:DTC) shares rose 17.2% to $5.34. Solo Brands recently reported worse-than-expected Q1 sales results.
- Express, Inc. (NYSE:EXPR) jumped 16% to $2.9575. Express recently reported better-than-expected Q1 sales results and raised its FY22 guidance.
- Carver Bancorp, Inc. (NASDAQ:CARV) jumped 15.6% to $11.29.
- Alpha Tau Medical Ltd. (NASDAQ:DRTS) gained 15.6% to $9.38.
- Amyris, Inc. (NASDAQ:AMRS) rose 15.2% to $2.6150.
- Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC) gained 15.2% to $3.7548.
- Opendoor Technologies Inc. (NASDAQ:OPEN) surged 14.3% to $7.45.
- Dell Technologies Inc. (NYSE:DELL) rose 12% to $49.24 after the company reported better-than-expected Q1 results.
- Ulta Beauty, Inc. (NASDAQ:ULTA) rose 11.4% to $421.12 after the company reported better-than-expected Q1 results and raised FY22 net sales guidance.
- Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) rose 9.6% to $5.50 after gaining over 7% on Thursday. Concert Pharmaceuticals recently announced topline results from its Phase 3 THRIVE-AA1 trial of CTP-543 in adult patients with moderate to severe alopecia areata (AA).
- Adicet Bio, Inc. (NASDAQ:ACET) rose 9% to $11.19 after reporting positive clinical update from ADI-001 Phase 1 Trial in relapsed/refractory Non-Hodgkin’s Lymphoma.
- Redbox Entertainment Inc. (NASDAQ:RDBX) rose 8.9% to $8.22 after gaining around 12% on Thursday. Redbox Entertainment recently acquired North American rights to WWII action-drama Come Out Fighting.
Losers
- Performance Shipping Inc. (NASDAQ:PSHG) shares fell 62% to $0.6910 after declining over 4% on Thursday.
- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) shares fell 54.1% to $6.94 after reporting clinical data for lifileucel in advanced melanoma. Piper Sandler and Chardan Capital lowered their price targets on the stock.
- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) dropped 54% to $14.18. SpringWorks Therapeutics highlighted Nirogacestat clinical data at the 2022 ASCO Annual Meeting .
- Mirati Therapeutics, Inc. (NASDAQ:MRTX) fell 43.6% to $32.96. Mirati Therapeutics reported positive results from the registration-enabling Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib 600 mg BID in patients with non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation who have received at least one prior systemic therapy.
- Aurora Cannabis Inc. (NASDAQ:ACB) dropped 36% to $1.75 as the company reported upsize to previously announced bought deal financing.
- Instil Bio, Inc. (NASDAQ:TIL) dipped 34.5% to $5.20 as the company reported the IND clearance of first CoStAR-TIL program, ITIL-306, designed to enhance activity in the tumor microenvironment.
- I-Mab (NASDAQ:IMAB) fell 26.3% to $8.33 as the company reported preliminary data of its ongoing Phase 2 clinical trial (NCT04322006) with uliledlimab, a differentiated CD73 antibody, and its global clinical development plan.
- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA) dipped 23.5% to $2.5950.
- Tempest Therapeutics, Inc. (NASDAQ:TPST) fell 22% to $3.0127.
- MSP Recovery, Inc. (NASDAQ:MSPR) dropped 21.7% to $2.0103.
- Mesa Royalty Trust (NYSE:MTR) dipped 21.5% to $18.62.
- Bright Green Corporation (NASDAQ:BGXX) dropped 15.7% to $6.65.
- SciSparc Ltd. (NASDAQ:SPRC) fell 14.6% to $2.8450. SciSparc announced pricing of $10 million private placement priced at-the-market.
- ToughBuilt Industries, Inc. (NASDAQ:TBLT) dropped 12% to $5.28.
- Big Lots, Inc. (NYSE:BIG) declined 10.5% to $27.35 after the company reported Q1 EPS results down from last year and worse-than-expected sales results.
- Citi Trends, Inc. (NASDAQ:CTRN) dropped 10.2% to $30.16. Citi Trends recently reported better-than-expected Q1 adjusted EPS and sales results.
- Workday, Inc. (NASDAQ:WDAY) fell 6.3% to $157.62 after the company reported worse-than-expected Q1 EPS results.
